These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 36383911)

  • 61. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibody-Drug Conjugates for Cancer Treatment.
    Lambert JM; Berkenblit A
    Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance study.
    Li X; Chen G; Hu Y; Zhao B; Jiang J
    Anticancer Drugs; 2022 Jan; 33(1):e228-e234. PubMed ID: 34538863
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
    Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
    J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Strategies and challenges for the next generation of antibody-drug conjugates.
    Beck A; Goetsch L; Dumontet C; Corvaïa N
    Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Juárez-Salcedo LM; Nimkar S; Corazón AM; Dalia S
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062823
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
    Oak E; Bartlett NL
    Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibody-drug conjugates as novel anti-cancer chemotherapeutics.
    Peters C; Brown S
    Biosci Rep; 2015 Jun; 35(4):. PubMed ID: 26182432
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
    Sapra P; Betts A; Boni J
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
    Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
    Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer.
    Alhalabi O; Altameemi L; Campbell MT; Meric-Bernstam F
    Cancer J; 2022 Nov-Dec 01; 28(6):417-422. PubMed ID: 36383903
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antibody-drug conjugates in cancer therapy.
    Sievers EL; Senter PD
    Annu Rev Med; 2013; 64():15-29. PubMed ID: 23043493
    [TBL] [Abstract][Full Text] [Related]  

  • 74. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
    Beck A; Senter P; Chari R
    MAbs; 2011; 3(4):331-7. PubMed ID: 21691144
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting cancer with antibody-drug conjugates: Promises and challenges.
    Dean AQ; Luo S; Twomey JD; Zhang B
    MAbs; 2021; 13(1):1951427. PubMed ID: 34291723
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate.
    Ladror D; Gu C; Tong V; Schammel A; Gavrilyuk J; Haight A; Sarvaiya H
    Drug Metab Dispos; 2024 Jan; 52(2):135-142. PubMed ID: 38050039
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Emerging antibody-drug conjugates for treating lymphoid malignancies.
    Wolska-Washer A; Robak P; Smolewski P; Robak T
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):259-273. PubMed ID: 28792782
    [TBL] [Abstract][Full Text] [Related]  

  • 80. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
    Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
    Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.